Nanoformulation of Artemisia afra and its potential biomedical applications in type 2 diabetes

Abstract

Current research classifies Type 2 diabetes as most prevalent non-communicable diseases in South Africa. Approximately 285 million people are affected globally with an expected increase to 595 million by the year 2035. Synthetic first-line drugs in the treatment of Type 2 diabetes, have been shown to have an efficacy rate of approximately 43% as a result of poor drug uptake and metabolism. Furthermore, given South Africa’s uniquely diverse botanical heritage, herbs commonly used traditional medicine have shown promise in the treatment of Type 2 diabetes.